1-20 of 1050
decitabine
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Free
Clinical Trials & Observations
Guillermo Garcia-Manero, Elizabeth A. Griffiths, David P. Steensma, Gail J. Roboz, Richard Wells, James McCloskey, II, Olatoyosi Odenike, Amy E. DeZern, Karen Yee, Lambert Busque, Casey O’Connell, Laura C. Michaelis, Joseph Brandwein, Hagop Kantarjian, Aram Oganesian, Mohammad Azab, Michael R. Savona
Journal: Blood
Blood (2020) 136 (6): 674–683.
https://doi.org/10.1182/blood.2019004143
Published: 2020
Journal Articles

Epigenetic reprogramming sensitizes immunologically silent EBV + lymphomas to virus-directed immunotherapy

Free
Tanner Dalton, Ekaterina Doubrovina, Dmitry Pankov, Raymond Reynolds, Hanna Scholze, Annamalai Selvakumar, Teresa Vizconde, Bhumesh Savalia, Vadim Dyomin, Christoph Weigel, Christopher C. Oakes, Alicia Alonso, Olivier Elemento, Heng Pan, Jude M. Phillip, Richard J. O’Reilly, Benjamin E. Gewurz, Ethel Cesarman, Lisa Giulino-Roth
Journal: Blood
Blood (2020) 135 (21): 1870–1881.
https://doi.org/10.1182/blood.2019004126
Published: 2020
Includes: Supplemental data
Journal Articles

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Free
Noam E. Kopmar, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Roland B. Walter, MDPhDMS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2214.
https://doi.org/10.1182/blood-2019-123315
Published: 2019
Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Free
Amer M. Zeidan, MBBS, MHS, Daniel A Pollyea, MD, Jacqueline S Garcia, MD, Andrew Brunner, MD, Fernando Roncolato, BMed, FRACP, FRCPA, Uma Borate, MD, Olatoyosi Odenike, MD, Ashish R. Bajel, FRACP, Anne Marie Watson, FRACP, FRCPA, MBBS, Katharina Götze, Florian Nolte, MD, Peter T. Tan, MBBS, Wan-Jen Hong, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Lori Gressick, BS, William Ainsworth, PhD, Jason Harb, PhD, Ahmed Hamed Salem, PhD FCP, John Hayslip, Ronan Swords, MD PhD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 565.
https://doi.org/10.1182/blood-2019-124994
Published: 2019
Journal Articles

Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacyitidine: A Retrospective Analysis from the Hellenic MDS Study Group

Free
Elena E. Solomou, MD, Alexandra Kourakli, MD PhD, Anna Vardi, MD PhD, Ioannis Kotsianidis, MD PhD, Panagiotis Zikos, MD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Aikaterini Palla, Athina Vyniou, Charalampos Pontikoglou, MD PhD, Panagiotis T Diamantopoulos, MD PhD, Theodoros Vassilakopoulos, MD, Aikaterini Megalakaki, Eleni Variami, Helen A. Papadaki, MD PhD, George Vassilopoulos, MD PhD, Achilles Anagnostopoulos, Argiris Symeonidis, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5417.
https://doi.org/10.1182/blood-2019-131003
Published: 2019
Journal Articles

A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Free
Veronica A Guerra, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Lucia Masarova, MD, Naveen Pemmaraju, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MDMSc, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Gautam M. Borthakur, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Koji Sasaki, MD, Koichi Takahashi, MD, Kiran Naqvi, MDMPH, Yesid Alvarado, MD, Maro N. Ohanian, DO, Nitin Jain, MD, Prithviraj Bose, MD, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Zeev E. Estrov, MD, Srdan Verstovsek, MD PhD, Naval G. Daver, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4237.
https://doi.org/10.1182/blood-2019-125974
Published: 2019
Journal Articles

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Free
Brian J Ball, Christopher Famulare, MS, Eytan M. Stein, MD, Martin S. Tallman, MD, Saar I. Gill, MD PhD, Benjamin M Manning, MD PhD, Jamie Koprivnikar, MD, James McCloskey, MD, Rebecca Testi, NP-C, BSN, RN, MSN, OCN, Najla Al Ali, M.Sc, David A Sallman, MD, Eric Padron, MD, Aaron D Goldberg, MD PhD, Rami S. Komrokji, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4241.
https://doi.org/10.1182/blood-2019-125113
Published: 2019
Journal Articles

Abnl Marro : An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes

Free
Michael R. Savona, MD, Pierre Fenaux, MD PhD, Eric Padron, MD, Mrinal M Patnaik, MDMBBS, Uwe Platzbecker, MD, Adam Seegmiller, MD PhD, Raphael Itzykson, MD PhD, Guillermo F. Sanz, MD PhD, Valeria Santini, MD, Eric Solary, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4273.
https://doi.org/10.1182/blood-2019-130722
Published: 2019
Journal Articles

Budget Impact of Glasdegib in Combination with Low-Dose Cytarabine for the Treatment of First-Line Acute Myeloid Leukemia in the United States

Free
Ha Anh Pham, MSc, Sandra Milev, Shujun Li, Denise Zou, Yannan Hu, PhD, Bart Heeg, PhD, Timothy J Bell, MHA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5852.
https://doi.org/10.1182/blood-2019-122709
Published: 2019
Journal Articles

Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

Free
Shelley Herbrich, MS, Antonio Cavazos, Cora Marie C Cheung, BSN, Lynette Alexander-Williams, Nicholas J. Short, MD, Jairo Matthews, Naval G. Daver, MD, Marina Y Konopleva, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1428.
https://doi.org/10.1182/blood-2019-128601
Published: 2019
Journal Articles

Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

Free
Jacqueline S Garcia, MD, Lillian Werner, Benjamin K. Tomlinson, MD, Michael Keng, MD, Myrna Nahas, MD, Andrew Brunner, MD, Samer K. Khaled, MD, Alexandra Savell, BS, Marlise Luskin, MDMS, David P. Steensma, MD, Martha Wadleigh, MD, Eric S. Winer, MD, Edwin P. Alyea, III, MD, Corey Cutler, MD MPH, FRCPC, Vincent T. Ho, MD, Donna S Neuberg, ScD, Nicole Cullen, Andreas Kantartzis, Ana Lako, Scott Rodig, MD PhD, R. Coleman Lindsley, MD PhD, Yael Flamand, Claire Manuszak, Ryan Brennick, Mariano Severgnini, Stephanie Andrews, Ilene Galinsky, Pavan Bachireddy, MD, Yohei Arihara, MD PhD, Jerome Ritz, MD, Matthew S. Davids, MD, Howard Streicher, MD, Catherine J. Wu, MD, Richard M. Stone, MD, Daniel J. DeAngelo, MD, Robert J. Soiffer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2015.
https://doi.org/10.1182/blood-2019-126238
Published: 2019
Journal Articles

The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells

Free
Carsten Riether, PhD, Tanja Chiorazzo, PhD, Amy J. Johnson, PhD, Christina Diane Drenberg, PhD, Khaja Waheeduddin Syed, BPharm, MS, Mahan Moshir, MSc, Anna Hultberg, PhD, Nicolas Leupin, Hans De Haard, Adrian F Ochsenbein, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3918.
https://doi.org/10.1182/blood-2019-127464
Published: 2019
Journal Articles

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Free
Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Marina Y Konopleva, MD PhD, Farhad Ravandi, MD, Courtney D. DiNardo, MDMSc, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3926.
https://doi.org/10.1182/blood-2019-131930
Published: 2019
Journal Articles

Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML

Free
Fiona C Brown, Jelena Urosevic, Urszula Polanska, Jan Cosaert, MD PhD, J. Elizabeth Pease, PhD, Giovanna Pomilio, Veronique Litalien, Jon Travers, PhD, Andrew H. Wei
Journal: Blood
Blood (2019) 134 (Supplement_1): 3930.
https://doi.org/10.1182/blood-2019-129564
Published: 2019
Journal Articles

The Comparison of Hypomethylating Agents (HMA) Monotherapy with HMA Combined with Intensive Chemotherapy for Intermediate / High-Risk MDS or AML

Free
Jiang Ji, Zhao Wang, MD PhD, Bing Han
Journal: Blood
Blood (2019) 134 (Supplement_1): 3903.
https://doi.org/10.1182/blood-2019-123335
Published: 2019
Journal Articles

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Free
Hong Zheng, MD PhD, Shin Mineishi, David F. Claxton, MD, Junjia Zhu, Chenchen Zhao, MD, Bei Jia, MD PhD, W. Christopher Ehmann, MD, Seema Naik, MD, Natthapol Songdej, Raymond J. Hohl
Journal: Blood
Blood (2019) 134 (Supplement_1): 3939.
https://doi.org/10.1182/blood-2019-125153
Published: 2019
Journal Articles

Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia

Free
Keith W. Pratz, MD, Andrew H. Wei, Daniel A Pollyea, MD, Brian A Jonas, MD PhD, Walter Fiedler, MD, Christian Recher, MD PhD, Wan-Jen Hong, MD, Jalaja Potluri, MD, Catherine Miller, PharmD, Gail J. Roboz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3897.
https://doi.org/10.1182/blood-2019-127423
Published: 2019
Journal Articles

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Free
Kara Cicero, MD MPH, Mark L Heaney, Todd L. Rosenblat, MD MS, Nicole Lamanna, MD, Joseph G. Jurcic, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3899.
https://doi.org/10.1182/blood-2019-130203
Published: 2019
Journal Articles

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Free
Annette E. Hay, Sarit Assouline, MD, Roland B. Walter, MD PhD MS, Richard F. Little, MD MPH, Anna Moseley, M.S., Sperling M Gail, MPH, CHES, Annie Im, MD, James M. Foran, MD, Jerald P. Radich, MD, Min Fang, MD PhD, Megan Othus, PhD, Harry P. Erba, MD PhD, Laura C. Michaelis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3905.
https://doi.org/10.1182/blood-2019-124320
Published: 2019
Journal Articles

Combined Heterozygous Loss of Tet2 and Dnmt3a Along with Expression of Flt3 ITD/WT results in Acute Myeloid Leukemia Which Responds to a Combination of FLT3 Inhibitor, APE1 Inhibitor and Decitabine

Free
Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Raghuveer Singh Mali, PhD, Zhigang Cai, PhD, Ruchi Pandey, PhD, Reuben Kapur, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3754.
https://doi.org/10.1182/blood-2019-131172
Published: 2019